Pfizer in talks over full license for COVID-19 vaccine in Singapore

SINGAPORE (Reuters) - Pfizer Inc is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.

Pfizer-BioNTech's COVID-19 vaccine has interim authorisation under the pandemic special access route in Singapore. The U.S. Food and Drug Administration granted full approval to the vaccine last month.

Kenneth Mak, Singapore's director of medical services, said in a briefing on Friday Pfizer and Moderna had not submitted applications for full registration to authorities.

Singapore has not made COVID-19 vaccination compulsory, saying the Pfizer and Moderna shots only have emergency approval, although it has limited activities such as eating out for the unvaccinated.

Some experts say full registration could pave the way https://www.reuters.com/business/healthcare-pharmaceuticals/calls-grow-among-experts-singapore-vaccine-mandate-covid-19-spikes-2021-09-21 to make vaccination mandatory.

(Reporting by Aradhana Aravindan and Chen Lin in Singapore; Editing by Ed Davies)

You May Also Be Interested In

• Pfizer Declares Second-Quarter 2024 Dividend
• United Rentals profit beats expectations on higher equipment demand
• Pfizer (PFE) Announces EC Approves EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options